Compare PPBT & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PPBT | SBFM |
|---|---|---|
| Founded | 2010 | 2006 |
| Country | Israel | United States |
| Employees | N/A | 50 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4M | 4.9M |
| IPO Year | 2014 | N/A |
| Metric | PPBT | SBFM |
|---|---|---|
| Price | $4.32 | $1.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $30.00 | $7.00 |
| AVG Volume (30 Days) | 10.7K | ★ 37.9K |
| Earning Date | 05-20-2026 | 04-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $40.47 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $0.95 |
| 52 Week High | $5.18 | $2.43 |
| Indicator | PPBT | SBFM |
|---|---|---|
| Relative Strength Index (RSI) | 52.48 | 56.44 |
| Support Level | $3.70 | $1.05 |
| Resistance Level | $4.39 | $1.24 |
| Average True Range (ATR) | 0.34 | 0.03 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 40.35 | 80.00 |
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.